Leman Yel1, Srinivasan Ramanuja, Sudhir Gupta. 1. Division of Basic and Clinical Immunology, Department of Medicine, University of California, Irvine, CA 92697, USA. lyel@uci.edu
Abstract
BACKGROUND: IgM deficiency is a dysgammaglobulinemia characterized by isolated low levels of serum IgM. Patients with IgM deficiency may exhibit various clinical manifestations. However, IgM deficiency still remains to be explored with regard to diagnosis and treatment. METHODS: Through a retrospective chart review, we investigated the clinical and immunological features of 15 symptomatic adult IgM-deficient patients who were referred to our immunology clinics over a 4-year period. RESULTS: The patients were comprised of 6 males and 9 females, with a mean age of 57.2 years. On initial evaluation, 12 patients (80%) presented with susceptibility to infections, 5 (33%) had atopic manifestations such as asthma and allergic rhinitis, 3 (20%) had both infections and atopy, 4 patients (28%) had fibromyalgia-like symptoms, 3 (20%) had autoimmune manifestations, and 1 patient had lymphoma. The mean serum IgM level was 27.4 mg/dl (range 14-39). Impaired specific antibody response to pneumococcal antigens in 5 out of 11 studied patients (45%) appeared to be a notable association. Subtle abnormalities in IgG subclasses, lymphocyte subsets and in vitro proliferative lymphocyte responses were observed. Five patients who were treated with intravenous immunoglobulin responded very well. CONCLUSION: We propose that a thorough immunological evaluation including specific antibody responses be undertaken in patients with IgM deficiency. IgM-deficient patients who present with recurrent/severe infections may benefit from immunoglobulin treatment particularly in the presence of impaired pneumococcal antibody responses. Copyright 2009 S. Karger AG, Basel.
BACKGROUND:IgM deficiency is a dysgammaglobulinemia characterized by isolated low levels of serum IgM. Patients with IgM deficiency may exhibit various clinical manifestations. However, IgM deficiency still remains to be explored with regard to diagnosis and treatment. METHODS: Through a retrospective chart review, we investigated the clinical and immunological features of 15 symptomatic adult IgM-deficientpatients who were referred to our immunology clinics over a 4-year period. RESULTS: The patients were comprised of 6 males and 9 females, with a mean age of 57.2 years. On initial evaluation, 12 patients (80%) presented with susceptibility to infections, 5 (33%) had atopic manifestations such as asthma and allergic rhinitis, 3 (20%) had both infections and atopy, 4 patients (28%) had fibromyalgia-like symptoms, 3 (20%) had autoimmune manifestations, and 1 patient had lymphoma. The mean serum IgM level was 27.4 mg/dl (range 14-39). Impaired specific antibody response to pneumococcal antigens in 5 out of 11 studied patients (45%) appeared to be a notable association. Subtle abnormalities in IgG subclasses, lymphocyte subsets and in vitro proliferative lymphocyte responses were observed. Five patients who were treated with intravenous immunoglobulin responded very well. CONCLUSION: We propose that a thorough immunological evaluation including specific antibody responses be undertaken in patients with IgM deficiency. IgM-deficientpatients who present with recurrent/severe infections may benefit from immunoglobulin treatment particularly in the presence of impaired pneumococcal antibody responses. Copyright 2009 S. Karger AG, Basel.
Authors: Luoping Zhang; Bryan A Bassig; Joseph L Mora; Roel Vermeulen; Yichen Ge; John D Curry; Wei Hu; Min Shen; Chuangyi Qiu; Zhiying Ji; Boris Reiss; Cliona M McHale; Songwang Liu; Weihong Guo; Mark P Purdue; Fei Yue; Laiyu Li; Martyn T Smith; Hanlin Huang; Xiaojiang Tang; Nathaniel Rothman; Qing Lan Journal: Carcinogenesis Date: 2012-12-30 Impact factor: 4.944
Authors: Magda Carneiro-Sampaio; Dewton Moraes-Vasconcelos; Cristina M Kokron; Cristina M A Jacob; Myrthes Toledo-Barros; Mayra B Dorna; Letícia A Watanabe; Ana Karolina B B Marinho; Ana Paula Moschione Castro; Antonio C Pastorino; Clóvis Artur A Silva; Maurício D Ferreira; Luiz V Rizzo; Jorge E Kalil; Alberto J S Duarte Journal: J Clin Immunol Date: 2013-01-29 Impact factor: 8.317